A Pilot Study of Pembrolizumab in Combination With Y90 Radioembolization in Subjects With Poor Prognosis Hepatocellular Carcinoma

Abstract Background Combination checkpoint inhibition therapy with yttrium-90 (Y90) radioembolization represents an emerging area of interest in the treatment of advanced hepatocellular carcinoma (HCC). HCRN GI15-225 is an open-label, single-arm multicenter, pilot study (NCT03099564). Methods Eligib...

Celý popis

Podrobná bibliografia

Vydané v:	The oncologist (Dayton, Ohio) Ročník 29; číslo 3; s. 270 - e413
Hlavní autori:	Yu, Shawn, Yu, Menggang, Keane, Barry, Mauro, David M, Helft, Paul R, Harris, William P, Sanoff, Hanna K, Johnson, Matthew S, O’Neil, Bert, McRee, Autumn Jackson, Somasundaram, Ashwin
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	US Oxford University Press 01.03.2024
Predmet:	Care and treatment Clinical Trial Results Combined modality therapy Hepatoma Liver cancer Medical prognosis Methods Pilot projects Radiotherapy United States pembrolizumab glass Y90 radioembolization hepatocellular carcinoma immunotherapy TARE
ISSN:	1083-7159, 1549-490X, 1549-490X
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!